Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 24Unknown 5Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 4Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Leukemia, Monocytic, Acute 2Leukemia 2Down Syndrome 2Neoplasms 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1

Interventions

vedolizumab 1Injections 1Genetic Testing 1Gene Expression Profiling 1Gemtuzumab 1Decitabine 1Daunorubicin 1Cytarabine 1Calcineurin Inhibitors 1CPX-351 1Azacitidine 1Amplified Fragment Length Polymorphism Analysis 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelomonocytic, Acute × Daunorubicin × Clear all
NCT01627041 2026-04-27

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
178 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡